Cognition Therapeutics Inc (CGTX) Stock Analysis

Cognition Therapeutics Inc (CGTX) is a publicly traded company in the HEALTHCARE sector. It trades at $1.25, carries a market capitalization of $119.93M. This page summarizes the public market data, fundamentals, and frequently asked questions for CGTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Cognition Therapeutics Inc currently has a Bullish sentiment score of 0.17.

About Cognition Therapeutics Inc

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Purchase, New York, dedicated to pioneering small molecule therapies for age-related neurodegenerative diseases and retinal disorders. With a robust focus on enhancing cognitive health and vision in the aging population, the company is actively advancing its innovative pipeline through cutting-edge research and development initiatives. Cognition Therapeutics's proprietary drug design capabilities posit...

GNG Research Analysis

GNG Research scores Cognition Therapeutics Inc (CGTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CGTX.

Frequently Asked Questions

Does CGTX pay dividends?

Cognition Therapeutics Inc (CGTX) does not currently pay a regular dividend.

What is CGTX's market cap?

Cognition Therapeutics Inc (CGTX) has a market capitalization of $119.93M with a current stock price of $1.25.